Delaware
|
001-32954
|
20-0077155
|
||
(State
or other jurisdiction
of
incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
No.)
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
5.02
|
Departure
of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain
Officers.
|
Name
|
Base Salary | Cash Bonus |
Stock Options
|
||
Michael
Fonstein
|
$ |
335,320
|
$ |
76,600
|
149,609
|
Yakov
Kogan
|
261,969
|
59,844
|
149,609
|
||
John
A. Marhofer, Jr.
|
220,054
|
50,269
|
149,609
|
||
Andrei
Gudkov
|
136,224
|
62,238
|
149,609
|
CLEVELAND BIOLABS, INC. | |||
|
By:
|
/s/ John A. Marhofer, Jr. | |
Name: John A. Marhofer, Jr. | |||
Title: Chief Financial Officer | |||